Medtronic Stock - Analyst views diverge as tariff overhang meets robust pipeline
18.06.2026 - 19:45:47 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 19:42 CET. Details in the imprint.
Medtronic plc (IE00BTN1Y115) remains the subject of mixed analyst sentiment as its solid therapy pipeline collides with tariff and pricing headwinds. A recent Zacks research note assigns the stock a cautious rating while highlighting growth bets in cardiac ablation, robotics, and hypertension management, and other commentary underscores the impact of a substantial tariff burden on margins according to analyst reports.
All news and analysis on Medtronic stock
Further updates on Medtronic stock, from earnings and guidance to regulatory and product news, can be found in the dedicated topic area and on the company’s investor relations pages.
What Zacks highlights
A fresh Zacks Equity Research update assigns Medtronic stock a Zacks Rank #4 (Sell), pointing to tariff, pricing, and currency exposure as factors that could limit upside even if operational execution remains solid.
At the same time, the note underscores three strategic growth pillars: cardiac ablation systems, surgical robotics, and renal denervation therapies for hypertension, all of which could underpin revenue over the medium term if adoption scales.
Focus on analysts and consensus
The Zacks analysis emphasizes that the balance of risks for Medtronic is currently tilted by macro and reimbursement pressures despite progress in new technologies such as Hugo robotic systems and Symplicity hypertension procedures.
Separately, a recent detailed commentary on Medtronic notes that the company has delivered its strongest annual revenue in around a decade, yet the stock is still down by double digits year-to-date as investors weigh growth against margin headwinds.
Tariffs and margin pressure
According to that commentary, Medtronic recently completed a roughly $550 million acquisition of Scientia Vascular, strengthening its portfolio in stroke and neurovascular care and signaling continued capital allocation toward higher-growth niches.
However, the report also flags an estimated $250 million tariff headwind that is forcing analysts to reassess near-term margin trajectories, even as the company integrates newly acquired technologies and pursues its broader cost initiatives.
How the chart looks this week
On the technical side, Medtronic shares trade around the high-$70 range on the New York Stock Exchange, with intraday indications near $79 according to recent market data from several quote services.
On European trading venues, the stock’s Xetra listing recently changed hands in the high-EUR 60s, placing it below shorter-dated moving averages and still meaningfully under its 52-week high, reflecting the fundamental cross-currents described by analysts.
The product and business behind the stock
Medtronic generates revenue primarily from medical devices and therapies across cardiovascular, neuroscience, diabetes, and surgical segments, including cardiac rhythm management implants, structural heart valves, insulin pumps, and a growing portfolio in robotics and neurovascular interventions.
Where the stock trades today
The shares of Medtronic plc (IE00BTN1Y115) trade on the New York Stock Exchange at about $79 per share as of 06/18/2026, 13:30 ET, alongside secondary listings in Europe that show broadly consistent valuation levels when translated into euros.
Key facts on Medtronic stock
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- WKN: A14M2J
- Ticker: MDT
- Venue: New York Stock Exchange
- Price (as of 06/18/2026, 13:30 ET): 79.00 USD
- Market cap: around 100,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: 08/20/2026 (company guidance and market estimates)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
